MedPath

Evaluation of medicinal use of Tukhm-e-Suddab (seeds of Ruta graveolens) in management of Atherosclerosis

Phase 2
Completed
Conditions
Health Condition 1: null- Apparently healthy, but diagnosed as atherosclerosis according to the periscope scale.
Registration Number
CTRI/2018/03/012714
Lead Sponsor
atioinal Institute of Unani Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

(a) Patient of either sex (b) Patients of age 25-60 years (c) Peripheral arterial diseases (PAD) (d) ABI <= 0.9 or (e) ASI > 80.

Exclusion Criteria

(a) Uncontrolled diabetes (HbA1c > 9) and hypertension (160 110 mm of Hg) (b) Severe systemic diseases like chronic kidney disease or congestive heart failure etc. (c) Pregnant and lactating women (d) Patient who fails to follow up or give consent.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the efficacy of Unani single drug Tukhme Suddab (seeds of Ruta graveolens) by assessing changes in Periscope (Ankle Brachial Index and Arterial Stiffness Index).Timepoint: Ankle Brachial Index (ABI): Oth, 30th,60th and 90th day. <br/ ><br>Arterial Stiffness Index (ASI): Oth, 30th,60th and 90th day.
Secondary Outcome Measures
NameTimeMethod
ipid profile includes cholesterol, triglyceride, HDL, and LDLTimepoint: Lipid profile: Oth, 30th,60th and 90th day.
© Copyright 2025. All Rights Reserved by MedPath